

CASE :CT2717 US - NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
YONG-JIN WU, ET AL
APPLICATION NO: 10/719,187
FILED: 11/21/2003
FOR: 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM CHANNEL OPENERS

ART UNIT: 1625
EXAMINER: COVINGTON, RAYMOND K

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This supplemental information disclosure statement is being provided to call the Examiner's attention to the reference cited on the attached form PTO-1449. A copy of this reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

The Commissioner is hereby authorized to charge any necessary fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is enclosed.

Respectfully submitted,

Date: Dec. 13, 2005

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Aldo A. Algieri, Ph.D.
Agent for Applicant
Reg. No. 31,697
Telephone: 203-677-6809

CASE : CT2717 US - NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

DEC 13 2005

IN RE APPLICATION OF
YONG-JIN WU, ET AL
APPLICATION NO: 10/719,187
FILED: 11/21/2003
FOR: 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM CHANNEL OPENERS

ART UNIT: 1625
EXAMINER: COVINGTON, RAYMOND K

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This supplemental information disclosure statement is being provided to call the Examiner's attention to the reference cited on the attached form PTO-1449. A copy of this reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

The Commissioner is hereby authorized to charge any necessary fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is enclosed.

Respectfully submitted,



Date: Dec. 13, 2005

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Aldo A. Algieri, Ph.D.
Agent for Applicant
Reg. No. 31,697
Telephone: 203-677-6809

Sheet 1 of 1

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CT-2717-NP

APPLICATION NO. 10/719,187

APPLICANT Wu, *et al.*

FILING DATE 21 Nov. 2003

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AM	GRIBKOFF, V.K., "The therapeutic potential of neuronal KCNQ channel modulators", <i>Expert Opinions Ther. Targets</i> (2003) 7(6) p. 737-748
	AN	
	AO	
	AP	
	AQ	

EXAMINER	DATE CONSIDERED	
----------	-----------------	--

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.